The acquisition augments LGC’s position in the clinical diagnostics QC market, complementing a wide breadth of existing manufacturing capabilities across calibration verification materials, molecular diagnostics and serology controls, clinical genomics reference materials and viral antigens.
Euan O’Sullivan, President & Chief Operating Officer, LGC, said, “We are really excited to be bringing Technopath’s full-fledged chemistry and immunoassay controls into LGC. Their multi-constituent quality control products will dovetail perfectly with the calibration verification, molecular and serology product portfolios within our Clinical Diagnostics business unit. We look forward to combining Technopath’s and LGC’s expertise to deliver unrivalled solutions for our customers.”
Malcolm Bell, Chief Executive Officer, Technopath Clinical Diagnostics, commented, “We are delighted to be joining LGC as an integral part of their fast-growing Clinical Diagnostics unit. Technopath and LGC are an excellent fit as we share a purpose and mission, to support our customers by providing an expanded breadth of capability, geographic reach and scale. Our test consolidated multi analyte QC products allow end-customer labs to optimize their entire QC testing strategy while reducing waste and storage requirements and most importantly, reporting patient results with enhanced confidence and greater accuracy.”
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>